42 results about "Paclitaxel Liposome" patented technology

The invention discloses a paclitaxel liposome and a preparation method thereof. The invention provides a liposome loaded with an active substance. The liposome comprises a blank liposome with ginsenoside as a membrane material shown in formula I and the active substance, wherein the active substance is paclitaxel; and the blank liposome has a membrane which contains a lipid substance and ginsenoside as shown in formula I. The paclitaxel liposome provided by the invention has the characteristics of good film-forming property, encapsulation efficiency, targeting property, long cycle, stability,safety and uniformity, and the preparation process is simple.

The invention relates to a liposome drug combination and a preparation method of the drug combination. The weights of the effective drug components are listed as follows: the weight of the admixture for hydrogenated soybean phosphatide and sheep brain lecithin with a weight ratio of 2:1 is 300 to 550; the weight of the admixture for cholesterol, stearamide and beta-sitosterol with a weight ratio of 1:1:0.1 is 200 to 400; the weight of the admixture for tiopronin and vitamin E with a weight ratio of 4:1 is 100 to 200; the weight of the admixture for polyethylene glycol-4000 and polyethylene glycol-6000 with a discretional weight ratio is 150 to 200; the weight of vitamin C is 150 to 180; the weight of the admixture for tert-butyl alcohol and anhydrous alcohol with a weight ratio of 1.5 to 2.2:0.01 to 0.05 is 4000 to 7000; the weight of the admixture for paclitaxel and polyene paclitaxel with a discretional weight ratio is 20 and 40; the weight of the admixture for diphenhydramine and cimetidine with a weight ratio of 1:6 is 350 to 500. The invention has the advantages of reducing the drug dosage by nearly one time, increasing the curative effect by over 15 percent, and greatly reducing the side effect of the drugs.

The invention belongs to the technical field of medicine and discloses paclitaxel liposomes and a preparation method thereof, mainly including long-circulation liposomes, paclitaxel thermosensitive liposomes and paclitaxel thermosensitive long-circulation liposomes. Its composition is 1%-30% paclitaxel, 1%-95% phospholipid, 0%-30% cholesterol, 0%-50% heat-sensitive excipient D, 0%-50% excipient G, 0-80% lyoprotectant, 0-10% octadecylamine, 0.001-50% antioxidant, appropriate amount of buffer salt. These are three new paclitaxel liposome preparations, which solve the problem of paclitaxel’s water insolubility. The long circulation of long-circulation liposomes and the thermosensitivity of thermosensitive liposomes can prolong the circulation time of paclitaxel in the body, improve the targeting of tumors, and thus enhance its anti-tumor effect.

The invention relates to the field of pharmaceutical antitumor drug preparations, in particular to a docetaxel composite slow-release agent and a preparation method thereof. The docetaxel composite slow-release agent is prepared by: compositing docetaxel powder and lecithin via tetrahydrofuran, washing via n-hexane, performing vacuum rotary evaporation, ultrafiltering, and lyophilizing. The docetaxel composite slow-release agent related herein has good stability; compared with docetaxel liposomes, the docetaxel composite slow-release agent has the advantages of high carrying capacity, long cycle, low toxicity, good treatment effect and the like since docetaxel and phospholipids take effect not through simple encapsulating of drug in a vesical via phospholipids but through weak interaction.

The present invention provides a paclitaxel-phospholipid / albumin composite nanoparticle and its preparation process, the steps are as follows: (1) configure paclitaxel, phospholipid, cholesterol and DSPE-PEG 2000 stock solution; (2) preparation of paclitaxel liposomes; (3) preparation of albumin (BSA) stock solution; (4) preparation of paclitaxel-phospholipid / albumin composite nanoparticles. The preparation method of the present invention is simple and can solve the problem of poor solubility of insoluble drugs in water. The preparation does not contain Cremophor EL, which avoids the toxic and side effects caused by these solubilizers during injection; the drug-phospholipid / albumin composite nanoparticles prepared by the present invention Unlike ordinary liposomes and albumin nanoparticles, DSPE‑PEG is added to the formulation 2000 The stability of the nanoparticles is increased, and the encapsulation rate is high, the particle size is small and uniform, and the particle size of the nanoparticles does not change significantly after being placed at room temperature for 2 weeks.